abstract |
The invention relates to compounds of formula (I), and to pharmaceutically acceptable salts thereof, wherein R and R1 are as defined herein. R2 is selected from the group consisting of (Ia), (Ib), (Ic) and (Id). The invention further relates to intermediates for the preparation of the compounds of formula (I), and to pharmaceutical compositions containing, and methods of using, the compounds of formula (I), or pharmaceutically acceptable salts thereof, for the inhibition of phosphodiesterase (PDE) type IV or the production of tumor necrosis factor (TNF) in a mammal. |